NT-112 is under clinical development by Neogene Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NT-112’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NT-112 overview
NT-112 is under development for the treatment of advanced solid tumors including metastatic non-small cell lung cancer, colorectal adenocarcinoma, pancreatic ductal adenocarcinoma, endometrial cancer. The therapeutic candidate is a TGFBR2 KO Armored TCR-T comprising of autologous T-cells genetically engineered to express HLA-C*08:02-restricted T cell receptors (TCR) targeting KRAS G12D mutation. It is administered through parenteral route.
Neogene Therapeutics overview
Neogene Therapeutics, a subsidiary of AstraZeneca Plc, operates as a pre-clinical stage biotechnology company that is engaged in the development, and manufacturing T cell receptor therapies for solid cancers. The company is headquartered in Santa Monica, California, the US.
For a complete picture of NT-112’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
